Mindray And WuXi PharmaTech’s Growth Strategy In 2Q: China Earnings Roundup (Part 1)
This article was originally published in PharmAsia News
PharmAsia News takes a closer look at how Chinese healthcare companies have fared against the backdrop of a global economic slowdown, starting with two of the country’s leading companies in their respective industries.
You may also be interested in...
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.